Kevin Kunzmann

MD Magazine's most popular stories this year ranged from new clinical insights, to physician-submitted columns, to perspectives on burnout in the workplace.

Anti-VEGF injection therapy is the proven choice of care for AMD and DME. Still, concerns about dosing, costs, and convenience persist into 2019.

The inhaled INBRIJA therapy is indicated to treat 'off' episodes in patients taking carbidopa/levodopa.

The analyzer tests samples with an infrared spectroscopy system, providing measurements of various nutrients. It is intended for use by trained personnel in clinical settings.

New options for BPDCN and PNH provide patients alternatives to more burdensome standard-of-care treatment.

With no distinctive definition for what constitutes asthma-COPD overlap, clinicians are advising both diseases become diagnosed and treated differently.

The community-based program intent on improving black men's blood pressure care will revamp its practice headed into 2019.

Investigators also found that opiate agonist therapy could have a positive effect in limiting reinfection rates after patients achieve SVR.

In 2018, investigators confirmed that one of the staple symptoms of multiple sclerosis—white matter demyelination—isn't always consistent.

The seemingly complicated maneuvers of getting patient’s cholesterol better can be resolved with common sense. What’s best for the patient?

Since the PCSK9 inhibitors were approved for cholesterol management by the FDA in 2015, they have been frequently compared.

Healthcare provider employment opportunies have risen 7.1%—an increase from 2017's reported rate of 5%. Where are the jobs in most demand?

The non-invasive device is now the first and only FDA product approved for the prevention of cluster headache.

How the opioid epidemic and high drug prices have brought the hepatitis C burden onto a younger population in 2018.

Currently available anemia therapies only provide benefit for about half of patients with a lower-risk myelodysplastic syndromes (MDS)-related condition—and about one-quarter of such patients dependent on red blood cell transfusions.

The odds ratio of patients on the therapy reaching ≥33% RBC transfusion burden reduction was 5 times greater than those on placebo.

The FDA has approved amifampridine (Firdapse) tablets as the first ever treatment of the rare autoimmune disorder, Lambert-Eaton myasthenic syndrome (LEMS) in adults.

The rare disease is associated with other autoimmune conditions including small cell lunger cancer, and is estimated to be prevalent in approximately 3 million people worldwide.

Progestin compound segesterone acetate, which would be combined with testosterone, is currently marketed for the use of hormonal contraception, and for the treatment of endometriosis.

A new study found the annual top-50 ranking is a reliable indicator of cardiovascular disease mortality and patient satisfaction.

What could have been uncovered is further evidence for a progressive-onset MS phenotype characterized by acute episodic inflammatory changes.

The septic shock therapy was approved by the FDA last December. How has it fared in its first year of real-world clinical use?

How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.

According to the FDA, patients who stop the therapy are at a severe risk of symptoms worsening than previously to them even starting therapy.

The biologic AR101 was previously shown to significantly desensitize peanut allergies in a pediatric and adolescent patient population.

HRS-1 is a rare, acute complication of liver cirrhosis characterized by life-threatening and rapid progression that can end in renal failure. Terlipressin, a vasopressin analogue, could become the first therapy approved for the treatment of HRS-1 in the US.

Officials are concerned the perpetual cycle of information sharing—by both pro- and anti-vaccination parents—is creating an echo chamber in the US.

The AR101 oral therapy—a biologic designed to desensitize peanut allergies, manufactured by Aimmune Therapeutics—is anticipated to be submitted for FDA approval in the next month.

The antibacterial therapy has been indicated for forms of the disease driven by E. coli.

In analysis, the therapy plus standard immunosuppressive therapy resulted in a complete response rate 27% greater than that historically observed in patients treated with lone IST, over 6 months.